Ascletis Acne Drug Shows Positive Phase Three Results
January 30, 2026 | 14:53
The biopharmaceutical company reported encouraging top-line data from its late-stage clinical trial evaluating a novel once-daily oral treatment for acne.
Ascletis Begins Phase Two Diabetes Drug Trial
January 26, 2026 | 11:40
The biopharmaceutical company commenced dosing patients in its thirteen-week American clinical study evaluating an oral GLP-1 receptor agonist for diabetes management.
Ascletis Advances ASC37 Triple Agonist to Clinical Stage
January 21, 2026 | 15:21
The biopharmaceutical company selected its once-monthly injectable candidate targeting three metabolic receptors for clinical trials, progressing its pipeline for diabetes and obesity treatment.
Ascletis gets FDA clearance for oral GLP 1 diabetes study
January 06, 2026 | 11:06
The approval allows a longer phase two trial for its oral weight loss and diabetes treatment candidate.
Ascletis announces NDA acceptance for acne drug Denifanstat in China
December 11, 2025 | 16:00
The first-in-class FASN inhibitor has entered the regulatory review process for treating acne in the Chinese market.
Ascletis bets on once-monthly ASC36 to fight obesity
October 30, 2025 | 15:15
Ascletis Pharma Inc. announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical development candidate.
Ascletis ASC47 Plus Semaglutide 2025: Body Weight Down Fifty Six Point Two Per Cent More
September 22, 2025 | 15:17
Phase II data set up late-stage trials, giving medical writers obesity drug combo keywords and full poster download.
Ascletis ASC40 Phase III 2025: FASN Inhibitor Cuts Acne Lesions Fifty Per Cent
September 18, 2025 | 11:04
Late-breaker at EADV shows once-daily pill beats placebo, giving skincare writers acne drug pipeline keywords and full poster PDF.
Ascletis ASC30 GLP-1R Data 2025: Oral Obesity Drug Cuts Weight Twelve Per Cent
September 17, 2025 | 15:58
Once daily pill rivals injectables, giving diabetes bloggers EASD 2025 keywords and a full poster PDF for search friendly coverage.
Ascletis pill shows once-daily PK win
August 28, 2025 | 18:28
Obesity patients cheer one-tablet hope—yet regulators await Phase III waistlines.
Ascletis Reports Stronger Weight-Loss Results With Dual Agonist Combo
August 18, 2025 | 14:44
Animal study shows ASC47 + ASC31 outperform rival treatments in obesity model.
Ascletis Unveils ASC47 Weight Loss Drug Candidate
August 13, 2025 | 18:00
Preclinical data shows stronger muscle-preserving results than current leading treatments.
Ascletis Begins Dosing in U.S. Phase IIa Study for Monthly GLP-1R Obesity Drug
July 28, 2025 | 11:00
One shot a month, major hope ahead—Ascletis targets obesity with science and strategy.
Ascletis Completes Dosing in US Obesity Drug Combo Trial
July 15, 2025 | 10:00
Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.
Ascletis begins US Phase IIa study of oral obesity drug
July 03, 2025 | 09:00
The trial marks a key step in developing a small molecule oral alternative in the booming weight-loss drug market.
1 2
Mobile Version